Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:45.521Z.
Calculation as of: 2026-10-06T16:57:45.521Z.
Quote observation: 2026-10-06T16:54:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a9e17458a879267a616e624bc5dc95fe16f3f590d16343b45edf8fcc71148c1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$355.34M
EV/EBITDA Ratio
N/A
TTM Avg
37.95x
3Y Avg
29.61x
5Y Avg
22.14x
Market Cap
$355.01M
EV/EBITDA Ratio
N/A
TTM Avg
40.38x
3Y Avg
40.38x
5Y Avg
40.38x
Market Cap
$353.96M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.81M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.70M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$374.20M
EV/EBITDA Ratio
N/A
TTM Avg
682.46x
3Y Avg
682.46x
5Y Avg
682.46x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocugen, Inc. (OCGN) | $361.15M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $361.60M | 5.40x | 4.73x | 7.57x | 7.31x |
| Opus Genetics, Inc. (IRD)vs › | $362.98M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $355.34M | N/A | 37.95x | 29.61x | 22.14x |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.01M | N/A | 40.38x | 40.38x | 40.38x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $353.96M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $349.81M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $374.20M | N/A | 682.46x | 682.46x | 682.46x |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $380.87M | N/A | 10.71x | 10.71x | 10.71x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
